NHS North of England Branded Medicines Tranche A & Annual Tranche
Estimated value
—
Awarded value
—
Suppliers
37
Lots
3
Published
15 Mar 2023
Description
NHS Framework for North of England Branded Medicines - Tranche A and Annual Tranche.<br/>Offer reference number: CM/PHR/20/5606<br/>CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/20/5606/02 - NHS Framework for North of England Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months<br/>CM/PHR/20/5606/03 - NHS National Framework Agreement for the supply of Risankizumab for South of England and London. Period of framework: 1 March 2023 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months
Scope
- Reference
- CM/PHR/20/5606
- Commercial tool
- Standalone contract
- Contract dates
- 01 Mar 2023 to 28 Feb 2025
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 37 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 3 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | CM/PHR/20/5606/01 - NHS Framework for North of England Branded - Tranche A | £167.7m | cancelled |
| 2 | CM/PHR/20/5606/02 - NHS Framework for North of England Branded - Annual Tranche | £481.3m | cancelled |
| 3 | CM/PHR/20/5606/03 - NHS Supply of Risankizumab for South of England & London | £4.7m | cancelled |